As of close of business last night, Mereo BioPharma Group plc’s stock clocked out at $1.02, up 5.15% from its previous closing price of $0.97. In other words, the price has increased by $+0.0500 from its previous closing price. On the day, 2325531 shares were traded. MREO stock price reached its highest trading level at $1.1700 during the session, while it also had its lowest trading level at $0.9020.
To gain a deeper understanding of MREO’s stock, we examine its different ratios.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on August 12, 2022, initiated with a Overweight rating and assigned the stock a target price of $4.
On May 05, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $10.
On April 05, 2021, Needham started tracking the stock assigning a Buy rating and target price of $10.Needham initiated its Buy rating on April 05, 2021, with a $10 target price.
As of this moment, Mereo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.27.
Stock Price History:
Over the past 52 weeks, MREO has reached a high of $1.85, while it has fallen to a 52-week low of $0.30. The 50-Day Moving Average of the stock is 0.7617, while the 200-Day Moving Average is calculated to be 0.9359.
It appears that MREO traded 641.87K shares on average per day over the past three months and 780.6k shares per day over the past ten days. A total of 124.99M shares are outstanding, with a floating share count of 124.99M. Shares short for MREO as of Oct 13, 2022 were 6.09M with a Short Ratio of 3.49M, compared to 6.75M on Sep 14, 2022.
As of right now, 0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.